Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 11, Issue 11, Pages 938-946
Publisher
Informa UK Limited
Online
2011-06-01
DOI
10.4161/cbt.11.11.15527
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR)
- (2012) S. D. Knight et al. MOLECULAR CANCER THERAPEUTICS
- MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity
- (2010) Euphemia Leung et al. CANCER BIOLOGY & THERAPY
- Molecular Target Class Is Predictive of In vitro Response Profile
- (2010) Joel Greshock et al. CANCER RESEARCH
- PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells
- (2010) Edita Aksamitiene et al. CELLULAR SIGNALLING
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- NVP-BEZ235 as a New Therapeutic Option for Sarcomas
- (2010) M. C. Manara et al. CLINICAL CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
- (2009) Krishna M. Vasudevan et al. CANCER CELL
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- (2009) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor
- (2009) K. R. Coser et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest
- (2008) Shingo Dan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started